Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04876651
Title	The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Recruitment	Recruiting
Gender	male
Phase	Phase III
Variant Requirements	Yes
Sponsors	Telix Pharmaceuticals (Innovations) Pty Ltd
Indications	prostate adenocarcinoma castration-resistant prostate carcinoma
Therapies	Docetaxel Enzalutamide 177Lu-J591 + Abiraterone + Prednisolone Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Enzalutamide Abiraterone + Prednisolone 177Lu-J591 + Docetaxel
Age Groups:	senior \| adult
Covered Countries	NZL \| AUS